COST EFFECTIVENESS OF PEMBROLIZUMAB AND IPILIMUMAB IN ADVANCED MELANOMA

被引：3
|
作者：
Lu, T. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1585
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN86
引用
收藏
页码：A149 / A149
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) VERSUS IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA IN CANADA
    Wang, J.
    Chabot, I
    El-Hadi, W.
    Xu, R.
    Pellissier, J.
    Iliopoulos, I.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A153 - A154
  • [2] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MELANOMA PREVIOUSLY TREATED WITH IPILIMUMAB IN PORTUGAL
    Silva Miguel, L.
    Vargas Lopes, F.
    Pinheiro, B.
    Wang, J.
    Xu, R.
    Pellissier, J.
    Laires, P. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
  • [3] COST EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) VERSUS IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA IN THE UNITED STATES
    Wang, J.
    Pellissier, J.
    Xu, R.
    Liu, F. X.
    Stevinson, K.
    Chmielowski, B.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A154 - A154
  • [4] Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naive Patients with Advanced Melanoma in the United States
    Wang, Jingshu
    Chmielowski, Bartosz
    Pellissier, James
    Xu, Ruifeng
    Stevinson, Kendall
    Liu, Frank Xiaoqing
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (02): : 158 - 158
  • [5] Pembrolizumab versus ipilimumab for advanced melanoma
    Bauer-Kemeny, Claudia
    [J]. AKTUELLE DERMATOLOGIE, 2018, 44 (07) : 302 - 302
  • [6] Pembrolizumab versus Ipilimumab in Advanced Melanoma
    Robert, Caroline
    Schachter, Jacob
    Long, Georgina V.
    Arance, Ana
    Grob, Jean Jacques
    Mortier, Laurent
    Daud, Adil
    Carlino, Matteo S.
    McNeil, Catriona
    Lotem, Michal
    Larkin, James
    Lorigan, Paul
    Neyns, Bart
    Blank, Christian U.
    Hamid, Omid
    Mateus, Christine
    Shapira-Frommer, Ronnie
    Kosh, Michele
    Zhou, Honghong
    Ibrahim, Nageatte
    Ebbinghaus, Scot
    Ribas, Antoni
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26): : 2521 - 2532
  • [7] Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal
    Miguel, Luis Silva
    Lopes, Francisca Vargas
    Pinheiro, Bernardete
    Wang, Jingshu
    Xu, Ruifeng
    Pellissier, James
    Laires, Pedro Almeida
    [J]. VALUE IN HEALTH, 2017, 20 (08) : 1065 - 1073
  • [8] COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA
    Tibet, B.
    [J]. VALUE IN HEALTH, 2018, 21 : S45 - S45
  • [9] Pembrolizumab versus Ipilimumab in advanced malignant Melanoma
    Bauer-Kemeny, Claudia
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2018, 143 (04) : 227 - +
  • [10] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR ADVANCED MELANOMA TREATMENT IN PORTUGAL
    Silva Miguel, L.
    Vargas Lopes, F.
    Pinheiro, B.
    Wang, J.
    Xu, R.
    Pellissier, J.
    Laires, P. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A729 - A729
12345